Galantamine for 12 weeks does not improve neurocognition or immune activation in ART-suppressed people with HIV

Galantamine for 12 weeks did not improve cognition or reduce inflammation in PWH/ART regardless of smoking status.

Authors

Institutions

Publication Details

Journal
AIDS
Published
2025-11-27
DOI
https://doi.org/10.1097/qad.0000000000004418
Primary Topic
Nicotinic Acetylcholine Receptors Study
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Galantamine for 12 weeks does not improve neurocognition or immune activation in ART-suppressed people with HIV

Andrew V. Kossenkov, Anjana Yadav, Toshitha Kannan, Ronald G. Collman et al.
AIDS
Nicotinic Acetylcholine Receptors Study
article

Galantamine for 12 weeks does not improve neurocognition or immune activation in ART-suppressed people with HIV

Andrew V. Kossenkov, Anjana Yadav, Toshitha Kannan, Ronald G. Collman, Rebecca L. Ashare, Mary E. Putt, Alisa J. Stephens-Shields, Antoneta Karaj
article en

Abstract

Galantamine for 12 weeks did not improve cognition or reduce inflammation in PWH/ART regardless of smoking status.

AIDSVol. 40(4)
The Wistar Institute (US), University at Buffalo, State University of New York (US), University of Pennsylvania (US)
Good health and well-being
Openalex Percentile: Top 37%
Nicotinic Acetylcholine Receptors Study
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.